These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 31132831

  • 1. [Hepatobiliary Manifestation of Inflammatory Bowel Disease].
    Seo KI, Kang SB.
    Korean J Gastroenterol; 2019 May 25; 73(5):248-259. PubMed ID: 31132831
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hepatobiliary manifestations of inflammatory bowel disease.
    Yarur AJ, Czul F, Levy C.
    Inflamm Bowel Dis; 2014 Sep 25; 20(9):1655-67. PubMed ID: 24874461
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.
    Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R.
    World J Hepatol; 2021 Dec 27; 13(12):1828-1849. PubMed ID: 35069993
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
    Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT.
    Aliment Pharmacol Ther; 2018 Mar 27; 47(6):753-762. PubMed ID: 29377235
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hepatotoxicity of agents used in the management of inflammatory bowel disease.
    Khokhar OS, Lewis JH.
    Dig Dis; 2010 Mar 27; 28(3):508-18. PubMed ID: 20926880
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.
    Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M, REPENTINA study, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group.
    Gut; 2010 Oct 27; 59(10):1340-6. PubMed ID: 20577000
    [Abstract] [Full Text] [Related]

  • 16. Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis.
    Pinnuck B, Lynch KD.
    Expert Opin Pharmacother; 2024 Sep 27; 25(13):1835-1849. PubMed ID: 39316754
    [Abstract] [Full Text] [Related]

  • 17. Pancreatic Disorders in Patients with Inflammatory Bowel Disease.
    Montenegro ML, Corral JE, Lukens FJ, Ji B, Kröner PT, Farraye FA, Bi Y.
    Dig Dis Sci; 2022 Feb 27; 67(2):423-436. PubMed ID: 33625614
    [Abstract] [Full Text] [Related]

  • 18. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis.
    Hardarson S, Labrecque DR, Mitros FA, Neil GA, Goeken JA.
    Am J Clin Pathol; 1993 Mar 27; 99(3):277-81. PubMed ID: 8447289
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hepatic manifestations of inflammatory bowel diseases.
    Restellini S, Chazouillères O, Frossard JL.
    Liver Int; 2017 Apr 27; 37(4):475-489. PubMed ID: 27712010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.